Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FF0J1
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $13,216
Award facts
- Contract value 100% obligated
- $13,216.18 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $13,216.18 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pens on January 8, 2026, with completion by January 9, 2026. This non-set-aside award will be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major pharmaceutical distributor specializing in medical supply chain support for federal agencies, particularly the Department of Defense and military healthcare systems. The delivery order leverages the company's existing indefinite delivery contract with DLA Troop Support Medical, a comprehensive global pharmaceutical support vehicle valued at $999,999,999 through December 2026 that enables the supply of a broad range of pharmaceutical products and medical commodities to military healthcare programs worldwide.
This contract represents a routine fulfillment under DLA's pharmaceutical procurement framework, which relies on established prime vendor relationships to supply critical medications to military treatment facilities and other federal healthcare systems. Dupixent (dupilumab) is a biologic immunosuppressant used primarily for treating moderate-to-severe atopic dermatitis, asthma, and other inflammatory conditions, making this a specialized medical commodity typical of the products delivered under the broader DLA IDC. AmerisourceBergen's selection reflects its demonstrated capability to meet federal procurement requirements through open competition and its established position as a critical supplier within the military healthcare supply chain.
Quick answers
Who was awarded contract SPE2DR26FF0J1?
SPE2DR26FF0J1 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 8, 2026.
How much is contract SPE2DR26FF0J1 worth?
The government has obligated $13,216 on SPE2DR26FF0J1.
Is contract SPE2DR26FF0J1 an order under another contract?
Yes. SPE2DR26FF0J1 is a delivery order under SPE2DR25D2005, an indefinite delivery contract.
Was contract SPE2DR26FF0J1 competed?
The extent of competition for SPE2DR26FF0J1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award